Literature DB >> 27742071

The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor.

Michael Y Choi1, Manoj Kumar Kashyap2, Deepak Kumar3.   

Abstract

Malignant B cells accumulate in the peripheral blood, bone marrow, and lymphoid organs of patients with chronic lymphocytic leukemia (CLL). In the tissue compartments, CLL shape a protective microenvironment by coopting normal elements. The efficacy of drugs that target these interactions further underscores their importance in the pathogenesis of CLL. While the B cell receptor (BCR) pathway clearly plays a central role in the CLL microenvironment, there is also rationale to evaluate agents that inhibit other aspects or modulate the immune cells in the microenvironment. Here we review the main cellular components, soluble factors, and signaling pathways of the CLL microenvironment, and highlight recent clinical advances. As the BCR pathway is reviewed elsewhere, we focus on other aspects of the microenvironment.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CXCL12; CXCR4; Chemokine; Chronic lymphocytic leukemia; Mesenchymal stromal cell; Microenvironment; Nurse-like cell; Stroma; Wnt

Mesh:

Substances:

Year:  2016        PMID: 27742071     DOI: 10.1016/j.beha.2016.08.007

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  8 in total

1.  Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.

Authors:  Barbara L Andersen; Neha Godiwala Goyal; David M Weiss; Travis D Westbrook; Kami J Maddocks; John C Byrd; Amy J Johnson
Journal:  Cancer       Date:  2018-05-14       Impact factor: 6.860

2.  Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.

Authors:  Manoj K Kashyap; Carlos I Amaya-Chanaga; Deepak Kumar; Brett Simmons; Nanni Huser; Yin Gu; Max Hallin; Kevin Lindquist; Rolla Yafawi; Michael Y Choi; Ale-Ali Amine; Laura Z Rassenti; Cathy Zhang; Shu-Hui Liu; Tod Smeal; Valeria R Fantin; Thomas J Kipps; Flavia Pernasetti; Januario E Castro
Journal:  J Hematol Oncol       Date:  2017-05-19       Impact factor: 17.388

3.  DAPK3 participates in the mRNA processing of immediate early genes in chronic lymphocytic leukaemia.

Authors:  Fraser Thomas; Katie B Holmes; Sarah Kreuz; Peter Hillmen; Pascal F Lefevre
Journal:  Mol Oncol       Date:  2020-05-03       Impact factor: 6.603

Review 4.  Non-Coding RNAs as Cancer Hallmarks in Chronic Lymphocytic Leukemia.

Authors:  Linda Fabris; Jaroslav Juracek; George Calin
Journal:  Int J Mol Sci       Date:  2020-09-14       Impact factor: 5.923

5.  Insights on TAM Formation from a Boolean Model of Macrophage Polarization Based on In Vitro Studies.

Authors:  Malvina Marku; Nina Verstraete; Flavien Raynal; Miguel Madrid-Mencía; Marcin Domagala; Jean-Jacques Fournié; Loïc Ysebaert; Mary Poupot; Vera Pancaldi
Journal:  Cancers (Basel)       Date:  2020-12-07       Impact factor: 6.639

6.  Microfluidic immuno-serology assay revealed a limited diversity of protection against COVID-19 in patients with altered immunity.

Authors:  Dongjoo Kim; Giulia Biancon; Zhiliang Bai; Jennifer VanOudenhove; Yuxin Liu; Shalin Kothari; Lohith Gowda; Jennifer M Kwan; Nicholas Carlos Buitrago-Pocasangre; Nikhil Lele; Hiromitsu Asashima; Michael K Racke; JoDell E Wilson; Tara S Givens; Mary M Tomayko; Wade L Schulz; Erin E Longbrake; David A Hafler; Stephanie Halene; Rong Fan
Journal:  bioRxiv       Date:  2022-09-02

7.  Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors.

Authors:  Erika Rimondi; Elisabetta Melloni; Arianna Romani; Veronica Tisato; Fabio Casciano; Gian Matteo Rigolin; Daniela Milani; Claudio Celeghini; Giorgio Zauli; Paola Secchiero; Rebecca Voltan
Journal:  Curr Oncol       Date:  2021-07-01       Impact factor: 3.677

8.  Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.

Authors:  Mustafa A Barbhuiya; Manoj K Kashyap; Vinuth N Puttamallesh; Rekha Vijay Kumar; Xinyan Wu; Akhilesh Pandey; Harsha Gowda
Journal:  Oncotarget       Date:  2018-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.